Does genetic testing identify disease-associated variants in patients with early-onset atrial fibrillation?
Genetic testing identifies disease-associated variants, primarily in cardiomyopathy genes, in 10% of patients with early-onset atrial fibrillation, supporting its clinical utility in this population.
In this cohort study, genetic testing identified a disease-associated variant in 10% of patients with early-onset AF (the percentage was higher if diagnosed before the age of 30 years and lower if diagnosed after the age of 60 years). Most pathogenic/likely pathogenic variants are in genes associated with cardiomyopathy. These results support the use of genetic testing in early-onset AF.
Yoneda et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: